Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07681596 · ClinicalTrials.gov registry record · Phase 1
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by AstraZeneca.
- Not yet
- Registry status
- Phase 1
- Development phase
- 101
- Enrollment target
NCT07681596 is a Phase 1 study that has not yet begun recruiting, run by AstraZeneca. The registered enrollment target is 101 participants.
The verdict
NCT07681596, a Phase 1 study, has not yet begun recruiting, sponsored by AstraZeneca.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 101 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.
Interventions
- DRUG Aldesleukin
- DRUG Daratumumab
- BIOLOGICAL AZD4045
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2026-07-09 |
| Est. Completion | 2029-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07681596
The ClinicalTrials.gov registry entry for NCT07681596 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Aldesleukin is the first listed.
NCT07681596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07681596 about?
NCT07681596 is a clinical study titled "A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.
What is the current status of trial NCT07681596?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2026-07-09. Estimated completion is 2029-10-30.
What interventions are being tested in trial NCT07681596?
The interventions under investigation include: Aldesleukin (DRUG), Daratumumab (DRUG), AZD4045 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07681596?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.